ESR1 and breast cancer: In brief, 4480 postmenopausal women with primary ER + BC were randomised 2:1 to receive either treatment with a non-steroidal AI (letrozole or anastrozole) for 2 weeks before and 2 weeks after surgery or to no perisurgical treatment.